We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Ipsen (IPN) Eur1

Sell:€104.40 Buy:€105.00 Change: €0.1 (0.10%)
Market closed |  Prices as at close on 23 February 2024 | Switch to live prices |
Change: €0.1 (0.10%)
Market closed |  Prices as at close on 23 February 2024 | Switch to live prices |
Change: €0.1 (0.10%)
Market closed |  Prices as at close on 23 February 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Ipsen SA is a France-based biopharmaceutical group specialized in specialty care. The Company operates globally through two segments: Specialty Care and Consumer Healthcare. In Specialty Care, the Company is focused on various therapeutic areas, including oncology, neurosciences and rare diseases. Its oncology portfolio includes Somatuline, Decapeptyl, Cabometyx and Onivyde. Its neuroscience portfolio includes Dysport, and in rare diseases key products are NutropinAq and Increlex. Its primary care portfolio includes Smecta, Forlax, Fortrans, Eziclen, and Tanakan. In oncology Ipsen focuses on a number of disease areas, which include neuroendocrine tumors, renal cell carcinoma, hepatocellular carcinoma and pancreatic cancer. In addition, the Company has specialism in neurotoxin research and operates three research and development centers located in France, the United Kingdom and the United States.

Contact details

65 Quai Georges Gorse
+33 (1) 58335000

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
€8.78 billion
Shares in issue:
82.64 million
Euronext Paris
Euronext 100

Key personnel

  • Marc De Garidel
    Chairman of the Board
  • David Loew
    Chief Executive Officer, Director
  • Antoine Flochel
    Vice Chairman of the Board
  • Aymeric Le Chatelier
    Chief Financial Officer, Executive Vice President
  • Regis Mulot
    Chief Human Resource Officer, Executive Vice President
  • Francois Garnier
    Executive Vice President, General Counsel, Chief Business Ethics Officer
  • Catherine Abi-habib
    Executive Vice President, Strategy, Transformation and Digital
  • Bartosz Bednarz
    Executive Vice President, Head of Global Product and Portfolio Strategy
  • Stewart Campbell
    Executive Vice President, President of Ipsen North America
  • Steven Hildemann
    Executive Vice President, Chief Medical Officer, Head of Global Medical Affairs, Patients Safety and Patients Affairs

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.